A Study of HMPL-453 in Patients With Advanced Solid Malignancies

A Phase I/II, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients With Advanced Solid Malignancies

This is a dose escalation study consisting of two stages: Dose-escalation stage (stage 1): Patients will take a single dose of HMPL-453 on Day 1 and will be followed for one week for safety observations. After one week of observation, if no safety issues occur, patients can continue multiple dosing of HMPL-453 QD (quaque die) and start on the DLT (Dose Limited Toxicity) assessment cycles. Each cycle consists of 28-days. Patients are required to draw blood samples for PK and safety analysis at specific time points during the treatment; Dose-Expansion Stage (Stage 2): This stage is to further evaluate the safety, tolerability, PD (pharmacodynamics) profile, and preliminary anti-tumor activity of HMPL-453 at the RP2D (recommended phase 2 dose) in approximately 10 patients with advanced solid tumor.

Study Overview

• Status: Unknown
• Conditions: Solid Tumor, Adult
• Intervention / Treatment: Drug: HMPL-453

Detailed Description

Dose-escalation stage (stage 1): Patients participating in the dose-escalation stage will take a single dose of HMPL-453 on Day 1 and will be followed for one week for safety observations. After one week of observation, if no safety issues occur, patients can continue multiple dosing of HMPL-453 QD and start on the DLT assessment cycles. Each cycle consists of 28-days. Patients are required to draw blood samples for PK and safety analysis at specific time points during the treatment.

The 3+3 design will be employed for the dose escalation and MTD ( maximum tolerated dose) determination. To limit the number of patients being exposed to potentially ineffective doses, one patient will be enrolled and dosed in the initial dose cohort. If there are no DLT or less than grade 2 toxicities of Common Terminology Criteria for Adverse Event ( CTC AE ) occur in the first treatment cycle, then the study will be escalated to the next dose cohort. Otherwise, the trial will revert to a standard 3+3 design.

Dose-Expansion Stage (Stage 2): This stage is to further evaluate the safety, tolerability, pharmacokinetics (PK) profile, and preliminary anti-tumor activity of HMPL-453 at the RP2D in approximately 60 patients with advanced solid tumor. Patients with FGFR ( Fibroblast Growth Factor Receptor) dysregulated advanced solid tumors, including but not limited to advanced urothelial bladder cancer, advanced cholangiocarcinoma (patients with cancers of the gallbladder or ampulla of Vater are not eligible) and others solid tumors are preferred to be enrolled.

Expansion stage will begin after dose-escalation stage is completed and the MTD/RP2D has been determined. Patients will receive HMPL-453 with 28-day treatment cycles until disease progression, death, intolerable toxicity, no longer benefiting from the study treatment per investigator's discretion, or withdrawal of consent, whichever comes first.

• Study Type: Interventional
• Enrollment (Actual): 33
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 10000
      • Beijing 307 Hospital
  • Guangdong
    • Guangzhou, Guangdong, China, 510000
      • Cancer center of SYSU

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 25 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• In the dose escalation stage, patients with locally advanced, or metastatic solid tumor who have failed, or intolerable to, standard therapies or for whom no standard therapies exist will be enrolled.
• In the dose expansion stage, patients with locally advanced, or metastatic solid tumor and FGFR dysregulation who have failed or intolerable to standard therapies or no standard therapies exist are to be enrolled.
• In the dose escalation stage: evaluable or measurable disease according to RECIST Version 1.1. In the dose expansion stage: measurable disease according to RECIST Version 1.1.
• Life expectancy of at least 12 weeks.
• ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1.

Exclusion Criteria:

• Prior or current treatment with any selective FGFR inhibitor.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: HMPL-453; Two strengths of HMPL-453 tablets (25 mg and 100 mg based on the free base) will be used for clinical studies. The drug products are coated tablets, which are packaged in white induction sealed HDPE (high-density polyethylene) bottles. HMPL-453 will be administered to patients as oral tablet(s) on a daily basis, until disease progression, intolerable toxicity, or death. Dose levels are to be potentially tested in this study include 50, 100, 200, 300, 400, and 500 mg/day

Drug: HMPL-453; oral administrative

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of DLTs by the NCI CTCAE v4.03	Incidence of DLTs by the NCI CTCAE v4.03	Cycle 1 (DLT assessment window 28 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of AEs and clinically significant laboratory abnormalities	incidence of any AEs associated to treatment	From first dose to 30 days after last dose of study treatment
maximum plasma concentration (Cmax)	maximum plasma concentration (Cmax) of HMP 453	From first dose to day 56 of multiple dosing period
time to reach maximum concentration (Tmax)	time to reach maximum concentration (Tmax) of HMP 453	From first dose to day 56 of multiple dosing period
terminal half-life (t1/2)	terminal half-life (t1/2) of HMP-453	From first dose to day 56 of multiple dosing period
area under the concentration-time curve (AUC0-t)	area under the concentration-time curve (AUC0-t) of HMP453	From first dose to day 56 of multiple dosing period
apparent clearance (CL/F)	apparent clearance (CL/F) of HMP 453	From first dose to day 56 of multiple dosing period
Serum phosphate level increases	to evaluate the fluctuate level of Serum phosphate level	From first dose to Day 21 of the last treatment cycle
Objective response rate (ORR)	per RECIST	Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks)
Duration of response (DoR)	from the date of response to progress or death	Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks)
Disease Control Rate (DCR)	the response rate of PR (partial response) +CR(complete response) +SD （stable disease）	Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks)
Change in tumor size	per RECIST to evaluate the change of target and non-target lesions	Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks)
Progression free survival (PFS)	Per RECIST 1.1	Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks)

Collaborators and Investigators

• Sponsor: Hutchison Medipharma Limited
• Investigators: Study Director: Weiss Yang, Doctor, HMPL

Study record dates

Study Major Dates

• Study Start (Actual): May 23, 2017
• Primary Completion (Actual): December 31, 2019
• Study Completion (Anticipated): June 30, 2020

Study Registration Dates

• First Submitted: May 17, 2017
• First Submitted That Met QC Criteria: May 18, 2017
• First Posted (Actual): May 19, 2017

Study Record Updates

• Last Update Posted (Actual): February 13, 2020
• Last Update Submitted That Met QC Criteria: February 12, 2020
• Last Verified: February 1, 2020

More Information

Terms related to this study

• Keywords: solid tumor; dose escalation; HMPL453
• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: 2015-453-00CH1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No